  Despite the availability of effective vaccines, the persistence of SARS-CoV-2
suggests that co-circulation with other pathogens and resulting multi-epidemics
may become increasingly frequent. To better forecast and control the risk of
such multi-epidemics, it is essential to elucidate the potential interactions
of SARS-CoV-2 with other pathogens; these interactions, however, remain poorly
defined. Here, we aimed to review the current body of evidence about SARS-CoV-2
interactions. To study pathogen interactions in a systematic way, we first
developed a general framework to capture their major components: sign,
strength, symmetry, duration, and mechanism. We then reviewed the experimental
evidence from animal models about SARS-CoV-2 interactions. Of the 14 studies
identified, 11 focused on the outcomes of co-infection with non-attenuated
influenza A viruses and generally demonstrated that co-infection increased
disease severity compared with either mono-infection. By contrast, the effect
of co-infection on the viral load of either virus was variable and inconsistent
across studies. Next, we reviewed the epidemiological evidence about SARS-CoV-2
interactions in human populations. Although numerous studies were identified,
only few were specifically designed to infer interaction and many were prone to
multiple biases, including confounding. Nevertheless, their results suggested
that influenza and pneumococcal conjugate vaccinations were associated with
reduced riskof SARS-CoV-2 infection. Finally, we formulated simple transmission
models of SARS-CoV-2 co-circulation with a viral or a bacterial pathogen,
showing how they can naturally incorporate the proposed framework. More
generally, we argue that such models, when designed with an integrative and
multidisciplinary perspective, will be invaluable tools to resolve the
substantial uncertainties that remain about SARS-CoV-2 interactions.
